We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Review |

Identification of Inflammatory Neuronal Injury and Prevention of Neuronal Damage in Multiple Sclerosis Hope for Novel Therapies?

Frauke Zipp, MD1; Ralf Gold, MD2; Heinz Wiendl, MD3
[+] Author Affiliations
1Focus Program Translational Neurosciences (FTN), Rhine Main Neuroscience Network, Department of Neurology (rmn2), University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany
2Department of Neurology, St Josef-Hospital/Ruhr University Bochum, Bochum, Germany
3Department of Neurology, University of Münster, Münster, Germany
JAMA Neurol. 2013;70(12):1569-1574. doi:10.1001/jamaneurol.2013.4391.
Text Size: A A A
Published online

Importance  Although multiple sclerosis (MS) has long been considered the prototype for an inflammatory, demyelinating disease of the central nervous system, modern histopathology and imaging techniques show that significant damage to neuronal structures already start occurring in the earliest stages of the disease. As the disease progresses, the extent of neuronal pathology accumulates. Therapeutic progress in terms of the prevention of increased disability has only just begun.

Objective  To review possible diagnostic improvements of neuronal compartment pathology as well as direct therapeutic interventions based on reports from the last decade and outline clinical results from studies and perspectives on the progression of MS.

Evidence Review  Literature search focused on publications and the references contained therein, relating to neuronal compartment pathology and direct therapeutic interventions published in the last decade in well-established peer-reviewed journals. The quality of the cited works was ensured by their acceptance by peer review, participation in clinical trials, and authors’ own expert assessment.

Findings  Current MS therapies as well as medications that are in late phase 3 trials or under approval exhibit primarily anti-inflammatory properties. However, clinical and imaging data demonstrate the potential of using novel therapies to prevent neuronal damage. Whether these exhibit effects on the neuronal compartment due to interference with the immune system or additional direct effects depends without question on the specific mechanism of action.

Conclusions and Relevance  Combining anti-inflammatory and direct neuroprotective, neuroregenerative/repair therapy strategies may open up new avenues in the treatment of MS.

Figures in this Article

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?


Place holder to copy figure label and caption
Divergent Activity of the Immune and Nervous Systems

The upper triangles depict the hypothesis regarding neural and immune homeostasis in multiple sclerosis (MS). The center section of the graph contains the most frequent clinical course, using blue bars for disability and the gray shaded area for atrophy increase during the MS disease. The bottom section contains the existing understanding of inflammatory activity in imaging and pathology. The underlying proinflammatory genetic predisposition of MS has been confirmed by the work of the International Multiple Sclerosis Genetics Consortium. At the beginning of MS, the central nervous system is clearly capable of retaining its homeostasis. From an Expanded Disability Status Scale (EDSS) score of 3 to 4 onward, there seems to be a stereotypical pattern for disability increase with a lack of immune attacks.31

Graphic Jump Location




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

13 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles